Browsing Category
Pharma Industry News
4667 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Iovance Biotherapeutics (NASDAQ: IOVA) holds 37% two-day gain after revenue guidance jumps 15%
Iovance raised the midpoint of its 2026 revenue outlook by $55 million after stronger Amtagvi and Proleukin demand, and the stock followed its 31.5% September 29 surge with another gain on September 30. The harder question is whether accelerating commercial adoption can now outrun cash burn and the risks inherent in scaling personalised cell therapy.
Sanofi pays $1bn upfront in Regeneron alliance worth up to $8bn
Sanofi and Regeneron Pharmaceuticals have reset their two-decade immunology alliance with four long-acting antibody programmes, a $1 billion upfront payment and as much as $7 billion of future milestones as Sanofi prepares for the eventual erosion of Dupixent exclusivity.
Why Novartis is paying $575m upfront for an mRNA immune-reset bet worth up to $7.8bn
Novartis has agreed to license Abogen Biosciences’ mRNA-encoded T-cell engager ABO2203 and secure options over additional RNA programs, committing $575 million upfront while leaving most of the headline $7.8 billion value contingent on future development, regulatory and commercial milestones.
Novo Nordisk licenses Hengrui weekly oral GLP-1/GIP drug in deal worth up to $2.6bn
HRS-1596 adds an oral GLP-1/GIP dual agonist to Novo Nordisk’s external pipeline only days after the company licensed technology aimed at monthly and quarterly injections.
Vectus Biosystems gains FDA pre-IND meeting for VB0004 pulmonary fibrosis drug candidate
Vectus Biosystems Limited has secured an FDA pre-IND meeting for VB0004 in idiopathic pulmonary fibrosis, advancing its lead antifibrotic programme toward a possible US clinical-development pathway.
uniQure shares tumble as Huntington’s gene therapy shows weaker four-year cUHDRS benefit
uniQure shares plunge as four-year ifezuntirgene data show mixed Huntington’s results while the gene therapy awaits FDA review.
Hengrui lands $2.6bn Novo Nordisk deal for experimental weekly oral obesity drug
Novo Nordisk licenses Hengrui’s weekly oral GLP-1/GIP drug HRS-1596 for up to $2.6 billion as obesity competition intensifies.
Cosmos Health (NASDAQ: COSM) orderbook tops 32.7m units after Target Pharma deals
Cosmos Health’s Cana Laboratories has added 5.2 million units through five-year Target Pharma manufacturing agreements, taking its orderbook above 32.7 million units as management attempts to convert an upgraded Athens plant into recurring production.
Summit Therapeutics (NASDAQ: SMMT) gives back most of 23% spike after AstraZeneca’s $2bn investment
AstraZeneca is investing $2 billion in Summit Therapeutics at an $18.36 common-equivalent price, yet Summit closed at only $16.39 after touching $19.01, showing that strategic validation has not erased the clinical and regulatory risk around ivonescimab.
ALX Oncology turns to biomarker-led development after evorpacept gastric cancer results
ALX Oncology’s evorpacept shows stronger activity in CD47-high HER2 tumors as the company seeks partners and prioritizes breast cancer.